(July 31, 2019) Amgen Korea (General Manager: Noh Sang-kyung) announced it has been named as ‘2019 Korea Exemplary Workplace’ by the Ministry of Employment and Labor in recognition of its efforts to create decent jobs consistently through ongoing employment programs and corporate cultural activities to improve a workplace environment and job quality.
The Korea Awards for Exemplary Workplace Practices was established by the Ministry of Employment and Labor in 2018 recognizes employers that contribute to job creation for the youth and the underserved population, as well as improvement in workplace practices. The award is the result of a rigorous assessment based on employment insurance data, recommendations from citizens, field inspections and references from labor organizations. A total of 100 employers of all sizes and types across the country are selected each year. For this year, Amgen Korea is the only multinational pharmaceutical company in Korea that was selected.
Amgen Korea received high marks for efforts to continue to improve working conditions with various initiatives to support work–life balance, as well as programs to improve job quality by hiring new employees on a continual basis to reduce average working hours.1 The company’s 2018 job growth surged by about 75 percent from the previous year thanks to its fast sales growth and expansion into new business areas. In particular, among the 81 new recruits hired in the past two years, 32 people or 39.5 percent are aged 34 years or below, showing its contribution to job creation for the youth. The company also helps the underserved population in employment by rehiring workers at post-retirement age and providing dispatched contract employees with the same welfare benefits as full-time workers.
In addition, Amgen Korea is active to reduce average working hours and improve job skills of employees. To ensure work-life balance with a 40-hour working week, the company has implemented end-of-year holiday, flexible working and working from home programs since 2016. The company also runs multiple programs designed to improve job skills and support career development of its employees.
“Since its founding in 2015, Amgen Korea has continued efforts to recruit excellent and diverse applicant pools and cultivate a good working environment. We are very excited that these efforts are being recognized through the 2019 Korea Awards for Exemplary Workplace Practices,” said Noh Sang-kyung, General Manager of Amgen Korea. “Amgen Korea has expanded its investment and support programs to ensure sustainable business growth to drive win-win situations with internal organizations of the company. Also, the company has contributed to the growth of the domestic job market. These activities are in line with our mission to “serve patients” and pave the way for bringing more innovative medicines to Korean patients. We remain committed to pursuing activities to improve job quality with a sense of mission as an exemplary job-creating enterprise in Korea.”
Amgen, a leading biotech company, set up its Korean operation in November 2015, and has since provided innovative biologic medicines to Korean patients in therapeutic areas of bone metabolism, cardiology and oncology with an aim to fulfill its mission to serve patients.
* amongst multinational pharmaceutical companies headquartered outside of Korea and operating a corporation in Korea
# # #
This media release was prepared to provide information on Amgen’s general business activities.Please take care not to risk potential violation of laws and regulations related to pharmaceutical advertising when referring to information contained in the media release.
About AmgenAmgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be the world’s largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information, visit www.amgen.com.
About Amgen KoreaAmgen Korea was established in November 2015 to further develop Amgen’s clinical pipeline which offers a wide range of products for bone disease, cardiovascular, oncology/hematology, nephrology, inflammation, neuroscience treatment and biosimilars, as well as to provide innovative medicines to patients in Korea who are suffering from severe diseases. As a member of the biotechnical industry, Amgen Korea will continue to contribute to the development of the Korean pharmaceutical industry by carrying forward diversified and positive activities.
Forward-Looking StatementsThis news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation.
We perform a substantial amount of our commercial manufacturing activities at a few key facilities and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to acquire other companies or products and to integrate the operations of companies we have acquired may not be successful.
A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.
CONTACT:Min-Jung Jung (mjung02@amgen.com)
Amgen Korea CPR: PR BOM